Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors as Adjunct Therapy to Statins: A New Frontier in Cardiovascular Risk Reduction.

Autor:	Lamia TH; Internal Medicine, Cox's Bazar Medical College, Cox's Bazar, BGD., Shah-Riar P; Internal Medicine, Doctors Hospital at Renaissance (DHR) Health, Edinburg, USA., Khanam M; Internal Medicine, Dhaka Medical College and Hospital, Dhaka, BGD., Khair F; Internal Medicine, Bangladesh Medical College, Dhaka, BGD., Sadat A; Internal Medicine, Dhaka Medical College and Hospital, Dhaka, BGD., Tania MK; Internal Medicine, Ibrahim Medical College and Birdem General Hospital, Dhaka, BGD., Haque SM; Internal Medicine, University of California, Riverside School of Medicine, Riverside, USA., Saaki SS; Internal Medicine, Dhaka Medical College and Hospital, Dhaka, BGD., Ferdausi A; Internal Medicine, Ibrahim Medical College, Dhaka, BGD., Naurin SA; Internal Medicine, Ibrahim Medical College, Dhaka, BGD., Tabassum M; Internal Medicine, Holy Family Red Crescent Medical College, Dhaka, BGD., Rahie RET; Internal Medicine, Dhaka Medical College and Hospital, Dhaka, BGD., Hasan R; Internal Medicine, Desert Valley Hospital, Victorville, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Oct 13; Vol. 16 (10), pp. e71365. Date of Electronic Publication: 2024 Oct 13 (Print Publication: 2024).
DOI:	10.7759/cureus.71365
Abstrakt:	Lowering low-density lipoprotein cholesterol (LDL-C) plasma levels is crucial for the prevention of primary and secondary cardiovascular diseases (CVDs). Many patients struggle to obtain goal LDL-C levels, despite the availability of several lipid-lowering medications, because of limited efficaciousness and unfavorable side effects. Proprotein convertase subtilisin/kexin type 9 (PCSK9) targeting has drawn interest recently as a novel approach to further lower cardiovascular (CV) risk. The number of receptors accessible to remove LDL-C from the bloodstream is reduced when PCSK9 attaches to LDL-C receptors and directs them toward lysosomal destruction. LDL receptor activity is increased by PCSK9 inhibition, which attracts therapeutic intervention. Despite concurrent statin therapy, phase 3 clinical trials have demonstrated encouraging outcomes with monoclonal antibodies against PCSK9, such as evolocumab and alirocumab, resulting in significant reductions in LDL-C levels. This study intends to investigate recent advancements in the field to evaluate PCSK9 inhibitors' safety, effectiveness, and potential for preventing CVD. The investigation will also review potential future paths and wider effects of using PCSK9 inhibitors in therapeutic settings. Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Lamia et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu